- Home
- ENTX vs FBIO Comparison
ENTX vs FBIO Comparison
Compare ENTX & FBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ENTX | FBIO |
|---|---|---|
| Founded | 2010 | 2006 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 142.0M | 113.9M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | ENTX | FBIO |
|---|---|---|
| Price | $1.71 | $4.43 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $10.00 | ★ $16.50 |
| AVG Volume (30 Days) | 219.0K | ★ 719.4K |
| Earning Date | 11-14-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $124,000.00 | ★ $62,303,000.00 |
| Revenue This Year | N/A | $29.71 |
| Revenue Next Year | N/A | $49.34 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 25.25 | N/A |
| 52 Week Low | $1.50 | $1.33 |
| 52 Week High | $3.22 | $4.39 |
Technical Indicators
Market Signals| Indicator | ENTX | FBIO |
|---|---|---|
| Relative Strength Index (RSI) | 39.34 | 78.79 |
| Support Level | $1.53 | $4.02 |
| Resistance Level | $1.99 | $4.34 |
| Average True Range (ATR) | 0.19 | 0.22 |
| MACD | -0.00 | 0.07 |
| Stochastic Oscillator | 32.73 | 100.00 |
Price Performance
Historical ComparisonAbout ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
About FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.